-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Today, Allergan, a subsidiary of AbbVie, announced the complete results of the research treatment AGN-190584 (pilocarpine 1.
Presbyopia affects nearly 2 billion people worldwide, and there are currently no effective drug solutions available for patients
AGN-190584 is an innovative and optimized ophthalmic formula of pilocarpine
The GEMINI 1 trial evaluated the efficacy and safety of AGN-190584 in 323 participants
Based on the results of GEMINI 1 and GEMINI 2, AbbVie has submitted a New Drug Application (NDA) for AGN-190584 to the US FDA
Note: The original text has been deleted
Reference materials:
[1] New Data Presented on the Safety and Efficacy of Investigational AGN-190584 as a Potential Novel Treatment for Presbyopia, a Common and Progressive Eye Condition.